KR20130067317A - 변비 우세형 과민성 대장 증후군을 치료하는 방법 - Google Patents

변비 우세형 과민성 대장 증후군을 치료하는 방법 Download PDF

Info

Publication number
KR20130067317A
KR20130067317A KR1020137013968A KR20137013968A KR20130067317A KR 20130067317 A KR20130067317 A KR 20130067317A KR 1020137013968 A KR1020137013968 A KR 1020137013968A KR 20137013968 A KR20137013968 A KR 20137013968A KR 20130067317 A KR20130067317 A KR 20130067317A
Authority
KR
South Korea
Prior art keywords
irritable bowel
bowel syndrome
ibs
constipation
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137013968A
Other languages
English (en)
Korean (ko)
Inventor
배리 쿼트
데이비드 로젠바움
Original Assignee
나포 팔마큐티칼스 인코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나포 팔마큐티칼스 인코퍼레이션 filed Critical 나포 팔마큐티칼스 인코퍼레이션
Publication of KR20130067317A publication Critical patent/KR20130067317A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020137013968A 2006-05-01 2007-04-30 변비 우세형 과민성 대장 증후군을 치료하는 방법 Ceased KR20130067317A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79707606P 2006-05-01 2006-05-01
US60/797,076 2006-05-01
PCT/US2007/067739 WO2007130892A2 (en) 2006-05-01 2007-04-30 Method for treatment of constipation-predominant irritable bowel syndrome

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR20087029447A Division KR20090009292A (ko) 2006-05-01 2007-04-30 변비 우세형 과민성 대장 증후군을 치료하는 방법

Publications (1)

Publication Number Publication Date
KR20130067317A true KR20130067317A (ko) 2013-06-21

Family

ID=38668465

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137013968A Ceased KR20130067317A (ko) 2006-05-01 2007-04-30 변비 우세형 과민성 대장 증후군을 치료하는 방법
KR20087029447A Ceased KR20090009292A (ko) 2006-05-01 2007-04-30 변비 우세형 과민성 대장 증후군을 치료하는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR20087029447A Ceased KR20090009292A (ko) 2006-05-01 2007-04-30 변비 우세형 과민성 대장 증후군을 치료하는 방법

Country Status (18)

Country Link
US (3) US7556831B2 (https=)
EP (2) EP2015639A4 (https=)
JP (2) JP2009535419A (https=)
KR (2) KR20130067317A (https=)
AU (1) AU2007248182B2 (https=)
CA (1) CA2650022C (https=)
CY (1) CY1113723T1 (https=)
DK (1) DK2241318T3 (https=)
ES (1) ES2401366T3 (https=)
HR (1) HRP20130203T1 (https=)
MX (1) MX2008013768A (https=)
NZ (3) NZ609280A (https=)
PL (1) PL2241318T3 (https=)
PT (1) PT2241318E (https=)
RS (1) RS52678B (https=)
SG (2) SG195538A1 (https=)
SI (1) SI2241318T1 (https=)
WO (1) WO2007130892A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
ES2616012T3 (es) 2006-05-01 2017-06-09 Napo Pharmaceuticals, Inc. Composiciones para tratar o prevenir enfermedad inflamatoria del intestino
SI2241318T1 (sl) 2006-05-01 2013-04-30 Napo Pharmaceuticals, Inc. Postopek za zdravljenje sindroma iritabilnega ÄŤrevesa s predominantno obstipacijo
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8436051B2 (en) * 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US8734867B2 (en) 2007-12-28 2014-05-27 Liveleaf, Inc. Antibacterial having an extract of pomegranate combined with hydrogen peroxide
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
WO2009131957A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
JP2012503005A (ja) * 2008-09-19 2012-02-02 インスティテュート フォア ワンワールド ヘルス イミダゾール誘導体およびトリアゾール誘導体を含む、化合物、組成物ならびに方法。
JP4565219B2 (ja) * 2008-12-26 2010-10-20 アサヒビール株式会社 ポリフェノール含有顆粒またはポリフェノール含有チュアブル錠剤およびその製造方法
RU2571924C2 (ru) 2009-03-04 2015-12-27 ЛайвЛиф, Инк., Способ и вещество для активируемого сайтом комплексообразования биологических молекул
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
AU2010303577B2 (en) * 2009-10-06 2015-10-22 Napo Pharmaceuticals, Inc. Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
CN107595836A (zh) 2010-10-31 2018-01-19 纳珀制药公司 用于治疗hiv相关性腹泻的方法和组合物
US9192635B2 (en) 2011-06-24 2015-11-24 Liveleaf, Inc. Method of treating damaged mucosal or gastrointestinal tissue by administering a composition comprising a mixture of pomegranate and green tea extracts and releasably bound hydrogen peroxide
US20120329736A1 (en) * 2011-06-24 2012-12-27 Huang Alexander L Treatment for gastrointestinal disorders using a selective, site-activated binding system
US8722040B2 (en) 2011-06-24 2014-05-13 Liveleaf, Inc. Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites
CN104902911A (zh) 2012-11-21 2015-09-09 Kbs研究有限公司 草药补充剂及其使用方法
US8716351B1 (en) 2012-12-23 2014-05-06 Liveleaf, Inc. Methods of treating gastrointestinal spasms
US9510880B2 (en) 2013-08-13 2016-12-06 Zimmer, Inc. Polyaxial locking mechanism
WO2015184109A1 (en) * 2014-05-29 2015-12-03 Jaguar Animal Health, Inc. Methods of treating diarrhea in adult non-human animals
US10282369B2 (en) * 2017-03-08 2019-05-07 Centri Technology, Inc. Fast indexing and searching of encoded documents
US11857510B2 (en) 2017-05-31 2024-01-02 Napo Pharmaceuticals, Inc. Methods and compositions for treating congenital diarrhea disorder
JP7328153B2 (ja) 2017-05-31 2023-08-16 ナポ ファーマシューティカルズ インク． 胆汁酸性下痢、小腸切除又は胆嚢除去及び短腸症候群に関連する下痢を治療するための方法及び組成物
WO2019014714A1 (en) * 2017-07-17 2019-01-24 smartDNA Pty Ltd DIAGNOSTIC METHOD OF DYSBIOSIS

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE446940B (sv) 1983-02-16 1986-10-20 Carl Axel Virdalm Medel for bekempande av sjukdomstillstand i matsmeltningsapparaten innehallande skal eller ytterdelar av ber eller frukter
US4698360B1 (en) 1985-04-09 1997-11-04 D Investigations Pharmacologiq Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof
DE3564370D1 (en) 1985-08-30 1988-09-22 Nestle Sa Dietetic product with depurating and antidiarrheal activity and process for its preparation
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
SI9011933A (sl) 1990-10-15 1998-06-30 TANIN SEVNICA Kemična industrija p.o. Kostanjev taninski ekstrakt, postopek za njegovo pridobivanje in njegova uporaba
US5234922A (en) 1992-09-28 1993-08-10 University Of Iowa Research Foundation Use of sulfonylureas and other potassium channel regulators to treat secretory diarrhea
EP2060183A3 (en) 1996-10-16 2009-06-03 Napo Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer antidiarrheal compositions
US6281240B1 (en) 1997-04-10 2001-08-28 Eli Lilly And Company Diarylsulfonylureas for use in treating secretory diarrhea
CN1215561A (zh) * 1997-10-27 1999-05-05 邢文海 保健茶
US7767203B2 (en) * 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
WO2000047062A2 (en) * 1999-02-01 2000-08-17 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer dietary supplements and methods for preparing same
CN1159054C (zh) 2002-01-22 2004-07-28 随志化 通腑止泻剂
US7235573B2 (en) 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
US20040063695A1 (en) 2002-09-30 2004-04-01 Alan Verkman Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US7208183B2 (en) 2002-10-05 2007-04-24 Bobrowski Paul J Methods and preparations of the latex from the croton species
US7303772B2 (en) * 2005-11-10 2007-12-04 Olalde Rangel Jose Angel Synergistic phytoceutical compositions
ES2616012T3 (es) 2006-05-01 2017-06-09 Napo Pharmaceuticals, Inc. Composiciones para tratar o prevenir enfermedad inflamatoria del intestino
SI2241318T1 (sl) 2006-05-01 2013-04-30 Napo Pharmaceuticals, Inc. Postopek za zdravljenje sindroma iritabilnega ÄŤrevesa s predominantno obstipacijo
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
AU2010303577B2 (en) 2009-10-06 2015-10-22 Napo Pharmaceuticals, Inc. Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
CN107595836A (zh) 2010-10-31 2018-01-19 纳珀制药公司 用于治疗hiv相关性腹泻的方法和组合物
EP2928560A4 (en) 2012-12-07 2016-06-01 Salix Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF HIV-ASSOCIATED DIARRHEA

Also Published As

Publication number Publication date
US20120128797A1 (en) 2012-05-24
EP2015639A4 (en) 2009-11-25
CA2650022A1 (en) 2007-11-15
RS52678B (sr) 2013-06-28
WO2007130892A3 (en) 2008-10-30
US20090238901A1 (en) 2009-09-24
JP2014058548A (ja) 2014-04-03
SG195538A1 (en) 2013-12-30
SI2241318T1 (sl) 2013-04-30
CY1113723T1 (el) 2016-06-22
ES2401366T3 (es) 2013-04-19
JP2009535419A (ja) 2009-10-01
CA2650022C (en) 2017-05-16
AU2007248182A1 (en) 2007-11-15
KR20090009292A (ko) 2009-01-22
NZ609280A (en) 2014-09-26
PL2241318T3 (pl) 2013-05-31
HRP20130203T1 (hr) 2013-04-30
WO2007130892A2 (en) 2007-11-15
SG161259A1 (en) 2010-05-27
US9138450B2 (en) 2015-09-22
DK2241318T3 (da) 2013-01-21
PT2241318E (pt) 2013-03-18
HK1143541A1 (en) 2011-01-07
EP2241318B1 (en) 2012-12-19
EP2015639A2 (en) 2009-01-21
AU2007248182B2 (en) 2013-05-23
US8067041B2 (en) 2011-11-29
NZ572049A (en) 2012-08-31
US7556831B2 (en) 2009-07-07
MX2008013768A (es) 2009-02-03
NZ595679A (en) 2013-04-26
EP2241318A1 (en) 2010-10-20
US20080031983A1 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
US9138450B2 (en) Method for treatment of constipation-predominant irritable bowel syndrome
EP2034844B1 (en) Method for treatment of diarrhea-predominant irritable bowel syndrome
US9987250B2 (en) Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer
AU2013205344B2 (en) Method for treatment of diarrhea-predominant irritable bowel syndrome
AU2013203794A1 (en) Method for treatment of constipation-predominant irritable bowel syndrome
HK1143541B (en) Method for treatment of constipation-predominant irritable bowel syndrome
HK1128861B (en) Method for treatment of diarrhea-predominant irritable bowel syndrome
HK1128861A (en) Method for treatment of diarrhea-predominant irritable bowel syndrome
HK1178383A (en) Compositions and methods for treating or preventing colon cancer
HK1131002B (en) Compositions for treating or preventing inflammatory bowel disease

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E601 Decision to refuse application
E801 Decision on dismissal of amendment
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000